These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 16313266)
1. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266 [TBL] [Abstract][Full Text] [Related]
2. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase. Calvo-Villas JM; Urcuyo BM; Umpierrez AM; Sicilia F Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571 [TBL] [Abstract][Full Text] [Related]
4. Rasburicase for the management of tumor lysis syndrome in neonates. McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218 [TBL] [Abstract][Full Text] [Related]
5. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561 [TBL] [Abstract][Full Text] [Related]
6. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006945. PubMed ID: 28272834 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. Knoebel RW; Lo M; Crank CW J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174 [TBL] [Abstract][Full Text] [Related]
8. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124 [TBL] [Abstract][Full Text] [Related]
9. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423 [TBL] [Abstract][Full Text] [Related]
10. Single 6-mg dose of rasburicase: The experience in a large academic medical center. Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China. Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962 [No Abstract] [Full Text] [Related]
12. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846 [TBL] [Abstract][Full Text] [Related]
14. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770 [TBL] [Abstract][Full Text] [Related]
15. Use of single-dose rasburicase in an obese female. Arnold TM; Reuter JP; Delman BS; Shanholtz CB Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497 [TBL] [Abstract][Full Text] [Related]
16. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574 [TBL] [Abstract][Full Text] [Related]
17. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134 [TBL] [Abstract][Full Text] [Related]
18. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients. Herrington JD; Dinh BC J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060 [TBL] [Abstract][Full Text] [Related]
19. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Vines AN; Shanholtz CB; Thompson JL Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516 [TBL] [Abstract][Full Text] [Related]
20. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. Bose P; Qubaiah O J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]